Aparna Vema

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1871459/publications.pdf

Version: 2024-02-01

11	144	7	11
papers	citations	h-index	g-index
11	11	11	185
all docs	docs citations	times ranked	citing authors

#	Article	IF	CITATIONS
1	Identification of novel HDAC8 selective inhibitors through ligand and structure based studies: Exploiting the acetate release channel differences among class I isoforms. Arabian Journal of Chemistry, 2022, 15, 103863.	4.9	3
2	Discovery of Novel Dihydropyrimidine and hydroxamic acid hybrids as potent Helicobacter pylori Urease inhibitors. Bioorganic Chemistry, 2021, 114, 105010.	4.1	18
3	Structure Activity Relationship, Drug Likeness and Evaluation of Antioxidant Activity of Some Mannich Bases of Dihydropyrimidinones. Asian Journal of Chemistry, 2019, 31, 1767-1773.	0.3	4
4	Discovery of novel potential selective HDAC8 inhibitors by combine ligand-based, structure-based virtual screening and in-vitro biological evaluation. Scientific Reports, 2019, 9, 17174.	3.3	25
5	A combined pharmacophore modeling, 3D QSAR, virtual screening, molecular docking, and ADME studies to identify potential HDAC8 inhibitors. Medicinal Chemistry Research, 2016, 25, 2434-2450.	2.4	4
6	P2–P1′ macrocyclization of P2 phenylglycine based HCV NS3 protease inhibitors using ring-closing metathesis. Bioorganic and Medicinal Chemistry, 2011, 19, 4917-4927.	3.0	12
7	Structure–activity relationships of HCV NS3 protease inhibitors evaluated on the drug-resistant variants A156T and D168V. Antiviral Therapy, 2010, 15, 841-852.	1.0	13
8	Improved P2 phenylglycine-based hepatitis C virus NS3 protease inhibitors with alkenylic prime-side substituents. Bioorganic and Medicinal Chemistry, 2010, 18, 5413-5424.	3.0	18
9	Discovery of achiral inhibitors of the hepatitis C virus NS3 protease based on 2(1H)-pyrazinones. Bioorganic and Medicinal Chemistry, 2010, 18, 6512-6525.	3.0	17
10	Insights into ligand selectivity in nitric oxide synthase isoforms: A molecular dynamics study. Journal of Molecular Graphics and Modelling, 2007, 26, 457-470.	2.4	5
11	Design of EGFR kinase inhibitors: A ligand-based approach and its confirmation with structure-based studies. Bioorganic and Medicinal Chemistry, 2003, 11, 4643-4653.	3.0	25